Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

mtDNA Damage in Alzheimer's Disease (AD)

Authors not listed

Duke University · 2018

Abstract

Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2018). mtDNA Damage in Alzheimer's Disease (AD). <em>Duke University</em>. https://clinicaltrials.gov/study/NCT03340571
Vancouver
Anonymous. mtDNA Damage in Alzheimer's Disease (AD). Duke University. 2018.
BibTeX
@misc{anon2018mtDNAD, title = {mtDNA Damage in Alzheimer's Disease (AD)}, author = {Anonymous}, journal = {Duke University}, year = {2018}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings